stockrow
Friday 6 November 2026
Export IDYA’s income statement to Excel — free account
IDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
31.20
0.55
+1.79%
Follow IDYA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.26 | 12.90 | 14.65 | 108.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.80) | (39.32) | (38.90) | (42.31) | |
P/B ratio |
2.99 | 3.15 | 2.86 | 3.62 | |
Price to Tangible BV |
2.99 | 3.15 | 2.86 | 3.62 | |
EV/Sales |
10.49 | 9.97 | 11.11 | 85.30 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(34.03) | (26.58) | (23.30) | (8.97) | |
EV/FCF |
(32.93) | (25.98) | (22.85) | (8.91) | |
Quick Ratio |
10.87 | 10.35 | 10.03 | 8.70 | |
Current Ratio |
11.34 | 10.74 | 10.45 | 9.04 | |
Net Debt/EBITDA |
6.74 | 6.18 | 6.78 | 6.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.21 | 0.22 | 0.20 | 0.03 | |
Operating CF/Net income |
1.09 | 0.76 | 0.78 | 0.74 | |
Capex/Depreciation |
1.02 | 14.22 | (8.41) | 1.52 | |
Research and Development Expense of Revenue |
796.24% | 1,459.24% | 1,227.15% | 1,187.03% | |
Selling, General and Administrative Expense of Revenue |
173.29% | 295.40% | 253.57% | 256.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
108.43% | 221.59% | 188.08% | 173.12% | |
Graham Net Nets |
0.19 | 0.20 | 0.22 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.73%) | (4.74%) | (5.15%) | (11.69%) | |
Free Cash Flow Yield |
(2.40%) | (2.98%) | (3.32%) | (8.84%) | |
Revenue per Share |
0.12 | 0.07 | 0.10 | 0.10 | |
Operating CF per Share |
(1.02) | (0.85) | (0.96) | (0.91) | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.03) | (0.86) | (0.97) | (0.91) | |
Cash per Share |
7.23 | 7.57 | 9.00 | 8.15 | |
Shareholders Equity per Share |
11.56 | 10.57 | 13.02 | 10.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.56 | 10.57 | 13.02 | 10.61 | |
Free Cash Flow |
(90.83) | (76.14) | (89.08) | (93.75) | |
Working Capital |
607.91 | 631.28 | 781.35 | 775.56 | |
Capital Expenditures |
(0.33) | (0.97) | (0.87) | (0.27) | |
Net Current Asset Value |
580.34 | 603.03 | 753.23 | 748.01 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.15 | 0.10 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
16.50 | 19.18 | 23.89 | 20.24 | |
Average Assets |
1,116.71 | 1,065.49 | 1,175.48 | 1,200.58 | |
Average Common Equity |
1,041.04 | 980.70 | 1,079.28 | 1,092.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026